National declines in the percentages of uninsured among adults aged 18-64 years with active epilepsy, 2010 and 2013 to 2015 and 2017-U.S. National Health Interview Survey

Drivers of US health care spending for persons with seizures and/or epilepsies, 2010-2018

OBJECTIVE

This study was undertaken to characterize spending for persons classified with seizure or epilepsy and to determine whether spending has increased over time.

METHODS

In this cross-sectional study, we pooled data from the Medical Expenditure Panel Survey (MEPS) household component files for 2010-2018. We matched cases to controls on age and sex of a population-based sample of MEPS respondents (community-dwelling persons of all ages) with records associated with a medical event (e.g., outpatient visit, hospital inpatient) for seizure, epilepsy, or both. Outcomes were weighted to be representative of the civilian, noninstitutionalized population. We estimated the treated prevalence of epilepsy and seizure, health care spending overall and by site of care, and trends in spending growth.

RESULTS

We identified 1078 epilepsy cases and 2344 seizure cases. Treated prevalence was .38% (95% confidence interval [CI] = .34-.41) for epilepsy, .76% (95% CI = .71-.81) for seizure, and 1.14% (95% CI = 1.08-1.20) for epilepsy or seizure. The difference in annual spending for cases compared to controls was $4580 (95% CI = $3362-$5798) for epilepsy, $7935 (95% CI, $6237-$9634) for seizure, and $6853 (95% CI = $5623-$8084) for epilepsy or seizure, translating into aggregate costs of $5.4 billion, $19.0 billion, and $24.5 billion. From 2010 to 2018, the annual growth rate in total spending incurred for seizures and/or epilepsies was 7.6% compared to 3.6% among controls.

SIGNIFICANCE

US economic burden of seizures and/or epilepsies is substantial and warrants interventions focused on their unique and overlapping causes.

Surgeon-Led Initiatives to Increase Access to Surgical Treatment of Epilepsy at an Academic Level 4 Epilepsy Center: An Observational Cohort Study

BACKGROUND

Underutilization of surgical treatment for epilepsy is multifactorial, and the multidisciplinary nature of caring for these patients represents a significant hurdle in expanding surgical treatment of epilepsy.

OBJECTIVE

To develop internal and external surgical referral relationships for patients with medically refractory epilepsy with the goal of improving access to care.

METHODS

To expand access to surgical epilepsy treatment at University of California (UC)-Irvine, 4 broad approaches focused on developing referral relationships and process improvement of surgical evaluation were undertaken in 2015 and 2016. The authors performed a retrospective review of all surgical epilepsy case referrals of the senior author from 2014 through 2020.

RESULTS

Epilepsy surgical volume at UC-Irvine increased from an average of 5.2 cases annually to 32 cases in the first year (2015) of implementation. There was continued case volume growth from 2015 through 2020 to 52 procedures in the most recent year (P = .03). Hospital payments for epilepsy procedures increased from $1.09M in 2015 to $2.02M and $1.8M in 2019 and 2020 (P < .01), respectively, while maintaining a diverse payer mix. 79.4% of these patients did not have a previously established option for surgical epilepsy care.

CONCLUSION

We outline strategies that level 4 epilepsy centers may use to strengthen collaborations and improve patient access for surgical epilepsy treatment. Increased collaboration can both improve the number of patients with epilepsy with access to specialized surgical care and produce reimbursement benefits for the centers caring for these patients, regardless of insurance source.

Difficulties obtaining private insurance reported by persons with epilepsy in Korea

PURPOSE

This study determined the proportion of persons with epilepsy (PWE) that possessed insurance policies and the difficulties they experienced in trying to obtain insurance in South Korea.

METHODS

Persons with epilepsy and healthy control subjects were asked to complete a questionnaire in which they were asked if they had experienced problems obtaining four types of insurance, including life, medical indemnity, critical illness, and motor insurance. Insurance policies obtained before diagnosis of epilepsy were excluded in the analysis.

RESULTS

This study included 106 adults with epilepsy and 87 healthy control subjects. The proportion of patients covered by at least one insurance type was significantly lower (54.7%) than that of controls (90.8%; p < 0.001). The proportions of patients insured did not differ according to freedom from seizures. Of 86 patients who tried to obtain insurance, 66% thought that it was much more difficult for them to obtain insurance than for those without epilepsy, and 48% had been refused one or more types of insurance because of their epilepsy. Difficulties in obtaining insurance differed depending on the types of insurance. Medical information about epilepsy was requested from 13% of patients. Of the insured patients, 71% did not disclose their epilepsy; 32% of these patients said it was because they were worried the insurance company would refuse to insure them.

CONCLUSIONS

Persons with epilepsy reported that obtaining private insurance was very difficult for them in South Korea. The findings suggest that PWE per se are excluded from private insurance in South Korea and emphasize the need for an evidence-based individual risk assessment for PWE.

CDC-supported epilepsy surveillance and epidemiologic studies: A review of progress since 1994

To report progress, to identify gaps, and to plan epilepsy surveillance and research activities more effectively, the Centers for Disease Control and Prevention (CDC) Epilepsy Program has summarized findings from selected CDC-supported surveillance and epidemiologic studies about epilepsy from 1994 through 2019. We identified publications supported by CDC funding and publications conducted by the CDC Epilepsy Program alone or with partners. We included only epilepsy surveillance and epidemiologic studies focusing on epilepsy burden, epilepsy-related outcomes, and healthcare utilization. We describe the findings of these studies in the following order: 1)prevalence; 2)incidence; 3)epilepsy-related outcomes by selected demographic characteristics; 4)cysticercosis or neurocysticercosis (NCC); 5)traumatic brain injury (TBI); 6)comorbidity; 7)mortality; 8)access to care; 9)quality of care; and 10) cost. We have characterized these findings in relation to the scope of the first three domains of the 2012 Institute of Medicine report on epilepsy and its relevant first four recommendations. From 1994 through 2019, 76 publications on epilepsy-related epidemiologic and surveillance studies were identified. Over the past 25 years, CDC has expanded community, state, and national surveillance on epilepsy and supported epidemiologic studies by using multiple assessment methods and validated case-ascertainment criteria to identify epilepsy burden, epilepsy-related outcomes, and healthcare utilization in the general population or in population subgroups. Among identified research opportunities, studies on epilepsy incidence and risk factors, mortality, and cost are considered as important surveillance gaps. Other remaining gaps and suggested surveillance strategies are also proposed. Findings from this review may help epilepsy researchers and other stakeholders reference and prioritize future activities for epidemiologic and surveillance studies in epilepsy.